NASC Collecting Safety Data Related to CBD Products, APPA Asks Its Members to Help

The American Pet Products Association (APPA) is calling on its members to help the National Animal Supplement Council (NASC) in its efforts of assembling “a dossier of credible safety data” on products containing cannabis and cannabis derivatives, including cannabidiol (CBD). Four species are being targeted: dogs, cats, horses and humans.

The collection of data, which is in conjunction with the University of Illinois, is to help establish a responsible pathway forward with such products, according to officials. The target date for completing the project is the end of March.

“Many NASC member companies have already submitted studies that have been forwarded to the University of Illinois, but the FDA has now announced that it has reopened the docket for submitting information the agency can evaluate,” Julia Fidenzio, vice president of government affairs and general counsel at APPA, said in a letter addressed to APPA members.

The FDA reopened the docket to “provide a public and transparent way for stakeholders to provide new and emerging information to us in real time as it becomes available,” FDA officials said in its post. “In the notice reopening the public docket, FDA outlined areas where data would be useful to inform FDA on the safety of CBD. This notice also includes instructions on how to submit data…To promote efficient and expeditious development of high-priority data on the safety of CBD, FDA has identified areas where it would be most helpful for clinical data to be generated to further address data gaps related to safety. This includes both specific clinical studies and the development of systematic surveillance. FDA is actively working to address these gaps, with the limited available funds for research, but also seeks collaboration and data from stakeholders.”

Fidenzio is encouraging any APPA member company who has CBD data, information or study results related to dogs, cats, horses or humans to submit it to NASC (email or directly to the FDA through the FDA docket.

Leave a Reply